Should I buy or sell Adaptimmune Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" ADAP shares. View ADAP analyst ratings or view top-rated stocks .

What is Adaptimmune Therapeutics' stock price target for 2024?

1 equities research analysts have issued 1 year target prices for Adaptimmune Therapeutics' shares. Their ADAP share price targets range from $1.00 to $4.00. On average, they predict the company's share price to reach $2.50 in the next year. This suggests a possible upside of 153.3% from the stock's current price. View analysts price targets for ADAP or view top-rated stocks among Wall Street analysts .

How have ADAP shares performed in 2024?

Adaptimmune Therapeutics' stock was trading at $0.7930 at the start of the year. Since then, ADAP shares have increased by 24.5% and is now trading at $0.9870. View the best growth stocks for 2024 here .

When is Adaptimmune Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ADAP earnings forecast .

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) issued its quarterly earnings results on Wednesday, March, 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.12. The biotechnology company had revenue of $0.23 million for the quarter, compared to analyst estimates of $4.80 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 155.39% and a negative net margin of 188.90%.

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com . Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE) , Xtrackers California Municipal Bond ETF (CA) , Endologix (ELGX) , Brainstorm Cell Therapeutics (BCLI) , Second Sight Medical Products (EYES) , Shopify (SHOP) , Micron Technology (MU) , BlackRock (BLK) , Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG) .

When did Adaptimmune Therapeutics IPO?

Adaptimmune Therapeutics (ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Key Client Fiduciary Advisors LLC (0.03%) and Columbia Advisory Partners LLC (0.00%). Insiders that own company stock include Adrian Rawcliffe , Cintia Piccina, Elliot Norry , Garry E Menzel, Gavin Wood, John Lunger and William C Bertrand Jr . View institutional ownership trends .

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ADAP

Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis

→ IRS Loophole Gives Americans An Escape From Inflation (From Birch Gold) (Ad)

Free ADAP Stock Alerts

$0.99

-0.04 (-3.89%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.93
▼
$1.05
50-Day Range: $0.99
▼
$1.75
52-Week Range: $0.42
▼
$2.05

Volume: 1.22 million shs
Average Volume: 1.32 million shs
Market Capitalization: $981.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

Get Adaptimmune Therapeutics alerts:

Adaptimmune Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Sell
1.00 Rating Score
Upside/Downside: 153.3% Upside
$2.50 Price Target
Short Interest: Healthy
0.32% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.46
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.44) to ($0.41) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.01 out of 5 stars

Medical Sector

799th out of 913 stocks

Biological Products, Except Diagnostic Industry

134th out of 150 stocks

2.5

Analyst's Opinion

Consensus Rating
Adaptimmune Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Adaptimmune Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.32% of the outstanding shares of Adaptimmune Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Adaptimmune Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Adaptimmune Therapeutics has recently increased by 2.89%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Adaptimmune Therapeutics does not currently pay a dividend.
Dividend Growth
Adaptimmune Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADAP.

2.5

News and Social Media Coverage

News Sentiment
Adaptimmune Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.
Search Interest
9 people have searched for ADAP on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.37% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Adaptimmune Therapeutics are expected to grow in the coming year, from ($0.44) to ($0.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Adaptimmune Therapeutics is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adaptimmune Therapeutics is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adaptimmune Therapeutics has a P/B Ratio of 24.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ADAP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ADAP Stock News Headlines

April 17, 2024 | americanbankingnews.com

Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.16

April 16, 2024 | markets.businessinsider.com

Maintaining Buy Rating on Adaptimmune Therapeutics Post-Genentech Collaboration Termination

April 18, 2024 | Birch Gold (Ad)

IRS Loophole Gives Americans An Escape From Inflation

In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.

April 14, 2024 | americanbankingnews.com

Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.29

April 12, 2024 | bizjournals.com

Adaptimmune shares drop as Genentech terminates potential $3B deal

April 12, 2024 | msn.com

Adaptimmune falls as Roche strategic collaboration ends

April 12, 2024 | americanbankingnews.com

Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 6.9%

March 26, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)

April 18, 2024 | Birch Gold (Ad)

IRS Loophole Gives Americans An Escape From Inflation

March 21, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)

March 15, 2024 | benzinga.com

Peter W. Sonsini's Net Worth

March 15, 2024 | finance.yahoo.com

ADAP Sep 2024 2.500 put

March 13, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading

March 13, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)

March 8, 2024 | seekingalpha.com

Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript

March 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Adaptimmune on Strong Clinical Results and Commercial Strategy

March 8, 2024 | finance.yahoo.com

Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

March 7, 2024 | benzinga.com

Adaptimmune Therapeutics Earnings Preview

March 7, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Adaptimmune on Upcoming Milestones and Promising Trial Results

March 7, 2024 | finance.yahoo.com

Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results

March 7, 2024 | finance.yahoo.com

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript

March 6, 2024 | investorplace.com

ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023

March 5, 2024 | markets.businessinsider.com

Adaptimmune Therapeutics earnings: here's what Wall Street expects

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Adaptimmune Following Reappointment of Key Executive and Strategic Commercialization Plan

February 29, 2024 | investing.com

Adaptimmune reappoints Cintia Piccina as chief commercial officer

February 28, 2024 | finance.yahoo.com

ADAP Apr 2024 1.500 put

February 27, 2024 | finance.yahoo.com

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

See More Headlines

Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ADAP
CUSIP: N/A
CIK: 1621227
Web: www.adaptimmune.com
Phone: 441235430000
Fax: 44-12-3543-0001
Employees: 449
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.50
High Stock Price Target: $4.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +153.3%
Consensus Rating: Sell
Rating Score (0-4): 1.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,870,000.00
Net Margins: -188.90%
Pretax Margin: -186.68%
Return on Equity: -155.39%
Return on Assets: -43.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.85
Quick Ratio: 2.85

Sales & Book Value

Annual Sales: $60.28 million
Price / Sales: 16.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.04 per share
Price / Book: 24.68

Miscellaneous

Outstanding Shares: 994,210,000
Free Float: 814,459,000
Market Cap: $981.29 million
Optionable: Optionable
Beta: 2.39

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Adrian G. Rawcliffe (Age 52)
CEO, Principal Accounting Officer & Director
Comp: $693.64k
Mr. Gavin Hilary James Wood ACA (Age 54)
BA (Hons), Chief Financial Officer
Comp: $508.22k
Mr. William C. Bertrand Jr. (Age 59)
Esq., J.D., Chief Operating Officer
Comp: $573.8k
Dr. Elliot Norry B.A. (Age 60)
M.D., Chief Medical Officer
Comp: $549.05k
Ms. Cintia Piccina Pharm.D. (Age 50)
Chief Commercial Officer
Comp: $597.44k
Dr. Helen Katrina Tayton-Martin MBA (Age 57)
Ph.D., Co-Founder & Chief Business & Strategy Officer
Comp: $709.84k
Ms. Joanna Brewer Ph.D. (Age 48)
Chief Scientific Officer
Dr. Juli P. Miller Ph.D.
VP of Corporate Affairs & Investor Relations
Ms. Kerry Sharp
Senior VP & General Council
Dana Lynch
Senior Director of Corporate Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ADAP Stock Analysis - Frequently Asked Questions

Should I buy or sell Adaptimmune Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" ADAP shares.
View ADAP analyst ratings or view top-rated stocks.
What is Adaptimmune Therapeutics' stock price target for 2024?: 1 equities research analysts have issued 1 year target prices for Adaptimmune Therapeutics' shares. Their ADAP share price targets range from $1.00 to $4.00. On average, they predict the company's share price to reach $2.50 in the next year. This suggests a possible upside of 153.3% from the stock's current price.
View analysts price targets for ADAP or view top-rated stocks among Wall Street analysts.
How have ADAP shares performed in 2024?: Adaptimmune Therapeutics' stock was trading at $0.7930 at the start of the year. Since then, ADAP shares have increased by 24.5% and is now trading at $0.9870.
View the best growth stocks for 2024 here.
When is Adaptimmune Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ADAP earnings forecast.
How were Adaptimmune Therapeutics' earnings last quarter?: Adaptimmune Therapeutics plc (NASDAQ:ADAP) issued its quarterly earnings results on Wednesday, March, 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.12. The biotechnology company had revenue of $0.23 million for the quarter, compared to analyst estimates of $4.80 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 155.39% and a negative net margin of 188.90%.
What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?: 6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).
When did Adaptimmune Therapeutics IPO?: Adaptimmune Therapeutics (ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.
Who are Adaptimmune Therapeutics' major shareholders?: Adaptimmune Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Key Client Fiduciary Advisors LLC (0.03%) and Columbia Advisory Partners LLC (0.00%). Insiders that own company stock include Adrian Rawcliffe, Cintia Piccina, Elliot Norry, Garry E Menzel, Gavin Wood, John Lunger and William C Bertrand Jr.
View institutional ownership trends.
How do I buy shares of Adaptimmune Therapeutics?: Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADAP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial